Dermapharm Holding SE (DMP.DE)

EUR 36.5

(-1.88%)

Net Income Summary of Dermapharm Holding SE

Dermapharm Holding SE's latest annual net income in 2023 was 62.36 Million EUR , down -53.54% from previous year.
Dermapharm Holding SE's latest quarterly net income in 2024 Q2 was 17.26 Million EUR , down -60.41% from previous quarter.
Dermapharm Holding SE reported an annual net income of 134.23 Million EUR in 2022, down -35.95% from previous year.
Dermapharm Holding SE reported an annual net income of 209.58 Million EUR in 2021, up 144.2% from previous year.
Dermapharm Holding SE reported a quarterly net income of 43.61 Million EUR for 2024 Q1, up 1719.12% from previous quarter.
Dermapharm Holding SE reported a quarterly net income of 24.84 Million EUR for 2023 Q3, up 370.43% from previous quarter.

Annual Net Income Chart of Dermapharm Holding SE (2023 - 2014)

Historical Annual Net Income of Dermapharm Holding SE (2023 - 2014)

Year	Net Income	Net Income Growth
2023	62.36 Million EUR	-53.54%
2022	134.23 Million EUR	-35.95%
2021	209.58 Million EUR	144.2%
2020	85.82 Million EUR	11.18%
2019	77.19 Million EUR	2.49%
2018	75.32 Million EUR	-3.11%
2017	77.74 Million EUR	362.1%
2016	16.82 Million EUR	32.46%
2015	12.7 Million EUR	20921.31%
2014	-61 Thousand EUR	0.0%

Year	Net Income	Net Income Growth
2024 Q2	17.26 Million EUR	-60.41%
2024 Q1	43.61 Million EUR	1719.12%
2023 Q3	24.84 Million EUR	370.43%
2023 Q4	-2.69 Million EUR	-110.84%
2023 FY	62.36 Million EUR	-53.54%
2023 Q1	49.4 Million EUR	65.28%
2023 Q2	-9.18 Million EUR	-118.6%
2022 Q1	37.37 Million EUR	-47.84%
2022 FY	134.23 Million EUR	-35.95%
2022 Q2	14.51 Million EUR	-61.15%
2022 Q4	29.89 Million EUR	-43.02%
2022 Q3	52.45 Million EUR	261.29%
2021 Q4	71.64 Million EUR	15.92%
2021 FY	209.58 Million EUR	144.2%
2021 Q2	39.81 Million EUR	9.66%
2021 Q3	61.8 Million EUR	55.22%
2021 Q1	36.31 Million EUR	47.98%
2020 Q4	24.53 Million EUR	8.33%
2020 FY	85.82 Million EUR	11.18%
2020 Q3	22.65 Million EUR	89.22%
2020 Q2	11.97 Million EUR	-55.1%
2020 Q1	26.66 Million EUR	42.38%
2019 Q2	20.06 Million EUR	4.72%
2019 FY	77.19 Million EUR	2.49%
2019 Q1	19.15 Million EUR	27.53%
2019 Q4	18.72 Million EUR	-2.73%
2019 Q3	19.25 Million EUR	-4.03%
2018 Q4	15.02 Million EUR	-32.68%
2018 FY	75.32 Million EUR	-3.11%
2018 Q2	16.6 Million EUR	-22.36%
2018 Q1	21.38 Million EUR	-65.12%
2018 Q3	22.31 Million EUR	34.38%
2017 Q2	4.78 Million EUR	-76.4%
2017 Q3	8 Million EUR	67.21%
2017 Q1	20.28 Million EUR	236.8%
2017 FY	77.74 Million EUR	362.1%
2017 Q4	61.31 Million EUR	665.84%
2016 FY	16.82 Million EUR	32.46%
2016 Q4	6.02 Million EUR	0.0%
2015 FY	12.7 Million EUR	20921.31%
2014 FY	-61 Thousand EUR	0.0%

Peer Net Income Comparison of Dermapharm Holding SE

Name	Net Income	Net Income Difference
MPH Health Care AG	29.54 Million EUR	-111.098%
Apontis Pharma AG	-11.3 Million EUR	651.785%
Evotec SE	-83.91 Million EUR	174.325%
MERCK Kommanditgesellschaft auf Aktien	2.82 Billion EUR	97.792%
PharmaSGP Holding SE	16.39 Million EUR	-280.362%
SynBiotic SE	-10.63 Million EUR	686.684%